Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4% - Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price dropped 3.4% during trading on Wednesday . The stock traded as low as $6.81 and last traded at $6.88. Approximately 4,370,890 shares changed hands during trading, a decline of 33% from the average daily volume of 6,568,276 shares. The stock had previously closed at $7.12.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RXRX. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $1.78 billion, a P/E ratio of -4.07 and a beta of 0.85. The business has a 50 day moving average price of $6.77 and a two-hundred day moving average price of $7.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the business posted ($0.43) EPS. The firm's revenue for the quarter was up 147.6% on a year-over-year basis. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company's stock, valued at approximately $4,697,960.96. This represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,788 shares of company stock worth $724,691. Company insiders own 15.75% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter worth about $25,000. Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares during the last quarter. KBC Group NV boosted its holdings in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after acquiring an additional 3,377 shares in the last quarter. Amalgamated Bank grew its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the third quarter valued at $69,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.